{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:44:26Z","timestamp":1777704266305,"version":"3.51.4"},"reference-count":23,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":51,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Appropriate targets for parathyroid hormone (PTH) in patients with chronic kidney disease (CKD) stages 3\u20135D are controversial, as are the means by which these targets might be achieved. Secondary hyperparathyroidism is linked to symptoms like bone pain and itch, in addition to less clinically overt issues like bone fragility as well as vascular and soft tissue calcification which may lead to adverse hard endpoints, particularly fracture and death. Recognized therapies for managing a rising PTH include vitamin D analogues, with or without calcimimetic (where available), in addition to management of serum mineral concentrations with diet, binders and dialysis. Despite these interventions, many patients eventually develop refractory metabolic abnormalities of severe hyperparathyroidism (HPT). Treatment decisions in severe HPT in Australia previously centred around whether to perform parathyroidectomy or use calcimimetics in combination with calcitriol (or its analogues) with goals of symptom relief, fracture reduction and reducing vascular risk. The decision to remove Pharmaceutical Benefits Scheme reimbursement for the calcimimetic cinacalcet during 2015, means that parathyroidectomy has now become the only treatment likely to benefit most patients with severe HPT who are medically fit for operative intervention. Although improvements in care are apparent for patients with CKD, there remains an urgent need for basic science and large international trials to inform better ways to manage HPT.<\/jats:p>","DOI":"10.1111\/nep.13029","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T05:40:22Z","timestamp":1492753222000},"page":"47-50","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism"],"prefix":"10.1111","volume":"22","author":[{"given":"Carmel M","family":"Hawley","sequence":"first","affiliation":[{"name":"Department Renal Medicine Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"Department Renal Medicine University of Queensland  Brisbane Queensland Australia"},{"name":"Australasian Kidney Trials Network University of Queensland  Brisbane Queensland Australia"},{"name":"Translational Research Institute  Woolloongabba, Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G","family":"Holt","sequence":"additional","affiliation":[{"name":"Department Nephrology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Medicine The University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12790"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.120"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013010103"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624"},{"issue":"1","key":"e_1_2_5_6_1","first-page":"S198","article-title":"Caring for Australasians with renal impairment. The CARI guidelines","volume":"11","author":"Hawley C","year":"2006","journal-title":"Biochem. Targets. Nephrol."},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414"},{"issue":"113","key":"e_1_2_5_8_1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease\u2010Mineral and Bone Disorder (CKD\u2010MBD)","author":"KDIGO CKD\u2010MBD Work Group","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.425"},{"key":"e_1_2_5_10_1","first-page":"791","article-title":"Article the effects of cinacalcet in older and younger patients on hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events ( EVOLVE )","author":"Parfrey PS","year":"2015","journal-title":"Trial"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.79"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-015-1106-x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-016-1447-7"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00972.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-248"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03520414"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.04.035"},{"key":"e_1_2_5_18_1","first-page":"1","article-title":"Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis","volume":"16","author":"Ishani A","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq725"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.09.024"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001754"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.19812"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.09.017"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnep.13029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nep.13029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T21:37:20Z","timestamp":1695677840000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nep.13029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":23,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/nep.13029"],"URL":"https:\/\/doi.org\/10.1111\/nep.13029","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2017-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}